Affinia receives FDA fast track designation for AFTX-201

​Affinia Therapeutics has received the US FDA fast track designation for AFTX-201, a genetic medicine under investigation for treating BAG3-associated DCM.

The post Affinia receives FDA fast track designation for AFTX-201 appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Droplet improves genomic analysis speed using NVIDIA Parabricks software
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Esperion to acquire Corstasis for cardiovascular franchise expansion
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
PHCbi unveils cell expansion system for research use 

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us